JSR Life Sciences to Launch Amsphere™ A+, a Next-Generation Protein A Resin for Antibody Drug Purification
17 September 2024
Tokyo, Japan – September 17, 2024 –JSR Life Sciences, a JSR Group company, today announced the launch of its next generation protein A chromatography resin, Amsphere™ A+. The resin will be presented at the BioProcess International Conference & Exhibition (BPI) 2024, September 23-26, 2024, in Boston, USA and at BioJapan to be held at Pacifico Yokohama from October 9-11, 2024.
Amsphere™ A+ uses a proprietary protein ligand and advanced polymer technology to significantly outperform its predecessor, Amsphere™ A3, in terms of binding capacity, alkali stability and pressure-flow property, resulting in improved efficiency of the production process.
Antibody drugs have become widely used as effective therapies for cancer and intractable diseases with high efficacy and minimal side effects. The production processes for these drugs are becoming highly sophisticated and complex due to the commercialization of bispecific antibodies and antibody-drug conjugates. With Amsphere™ A+, high reliability and improved production efficiency can be expected in the antibody drug manufacturing process.
Launched in 2016, Amsphere™ A3 has been well received in the market and used in more than 150 protein therapeutics manufacturing programs including commercial phase production. JSR Life Sciences also provides best-in-class research products and services to its partners for drug discovery, development and manufacturing through its unique products, services, and globally operating affiliates.
JSR Life Sciences will respond promptly to the needs of the global market with its unique products and services providing a complete offering from research through commercialization and technical support.
Share with friends:
16 May 2024
JSR to make Yamanaka Hutech, a manufacturer of high-purity chemicals for semiconductors, a wholly owned subsidiary
30 November 2023
New Energy Collaborative Aims to Accelerate Creation of Low-Carbon Energy Access in Asia-Pacific for the Semiconductor Climate Consortium
2 November 2022
JSR Joins Semiconductor Climate Consortium as Founding Member
JSR Corporation today announced it has become a founding member of the new Semiconductor Climate Consortium (SCC), a group formed with other companies from across the semiconductor value chain and SEMI, the global industry association representing the electronics manufacturing and design supply chain.
13 October 2022
JSR Electronic Materials Korea to be a JSR Wholly Owned Subsidiary
SR Corporation (Representative Director, CEO: Eric Johnson, “JSR”) announced today that it has signed a Share Purchase Agreement to acquire the 60% of shares held by PERI Corporation (“PERI”) and make JSR Electronic Materials Korea Co., Ltd. ("JEMK") a wholly owned subsidiary of JSR. JEMK is a joint venture between PERI and JSR, which is the sales agent/distributor of its Electronic Materials business in Korea.
15 March 2022
JSR Life Sciences’ Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy
11 October 2021
